ARQT - Arcutis Biotherapeutics  - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ARQT is currently covered by 9 analysts with an average price target of $26.46. This is a potential upside of $16.99 (179.41%) from yesterday's end of day stock price of $9.47.

Arcutis Biotherapeutics 's activity chart (see below) currently has 36 price targets and 64 ratings on display. The stock rating distribution of ARQT is 84.21% BUY and 15.79% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 18.78% with an average time for these price targets to be met of 43.69 days.

Highest price target for ARQT is $18, Lowest price target is $11, average price target is $26.46.

Most recent stock forecast was given by SERGE BELANGER from NEEDHAM on 07-Nov-2024. First documented stock forecast 25-Feb-2020.

Currently out of the existing stock ratings of ARQT, 32 are a BUY (84.21%), 6 are a HOLD (15.79%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$18

$8.74 (94.38%)

$18

13 days ago
(07-Nov-2024)

1/15 (6.67%)

$7.34 (68.86%)

102

Buy

$18

$8.74 (94.38%)

$17

6 months 5 days ago
(15-May-2024)

2/16 (12.5%)

$8.76 (94.81%)

58

Hold

$11

$1.74 (18.79%)

$6

8 months 23 days ago
(28-Feb-2024)

2/4 (50%)

$0.59 (5.67%)

55

Buy

$11

$1.74 (18.79%)

$10

10 months 30 days ago
(21-Dec-2023)

2/8 (25%)

$8.4 (323.08%)

89

Buy

$10

$0.74 (7.99%)

$45

1 years 7 days ago
(13-Nov-2023)

1/3 (33.33%)

$7.89 (373.93%)

106

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ARQT (Arcutis Biotherapeutics ) average time for price targets to be met?

On average it took 43.69 days on average for the stock forecasts to be realized with a an average price target met ratio 18.78

Which analyst has the current highest performing score on ARQT (Arcutis Biotherapeutics ) with a proven track record?

GRAIG SUVANNAVEJH

Which analyst has the most public recommendations on ARQT (Arcutis Biotherapeutics )?

Graig Suvannavejh works at GOLDMAN SACHS and has 3 price targets and 3 ratings on ARQT

Which analyst is the currently most bullish on ARQT (Arcutis Biotherapeutics )?

Louise Chen with highest potential upside - $40.74

Which analyst is the currently most reserved on ARQT (Arcutis Biotherapeutics )?

Chris Shibutani with lowest potential downside - -$3.26

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?